Gallium nitrate

Acute Tubular Necrosis — representative incidence ~10%.

Nephrotoxicity is the dose-limiting toxicity. At the approved antihypercalcemic dose (200 mg/m2/day by continuous IV infusion x 5 days) a rise in serum creatinine is reported in roughly 10% of patients; at higher antineoplastic doses it is far more frequent — e.g., dose-limiting azotemia in 4 of the first 10 patients (40%) at 700 mg/m2 in the SWOG advanced-bladder-cancer trial, which forced a longer inter-cycle interval. Precise incidence is uncertain because the supporting trials are small and heterogeneous, so the headline figure should be read with caution.

Source: PMID 15966562

Reported injury signatures: Acute Tubular Necrosis, Prerenal / Hemodynamic AKI, Electrolyte Disturbance.

1. Acute Tubular NecrosisPrimary
2. Prerenal / Hemodynamic AKISecondary
3. Electrolyte DisturbanceSecondary

Acute (~1–7 days) — During or within a few days of the 5-day continuous infusion — usually within the first week; creatinine trends back toward baseline once the drug is stopped and hydration is maintained.

• Pre-existing renal impairment (baseline serum creatinine above ~2.5 mg/dL is a contraindication)
• Volume depletion / inadequate hydration during the infusion
• Concurrent nephrotoxins — aminoglycosides, amphotericin B, IV contrast, cisplatin/ifosfamide
• Higher (antineoplastic) doses and bolus rather than continuous-infusion administration
• The underlying severe hypercalcemia itself, which drives a nephrogenic diabetes insipidus and prerenal azotemia
• Older age and other comorbid renal insults

• Rehydrate the patient and establish a brisk urine output (~2 L/day) before starting, and maintain hydration throughout the 5-day course
• Do not initiate if serum creatinine exceeds ~2.5 mg/dL
• Administer as a slow continuous IV infusion rather than a bolus
• Avoid or hold concurrent nephrotoxins (aminoglycosides, amphotericin B, IV contrast) during therapy
• Check serum creatinine daily and stop for a rising value
• Prefer a less nephrotoxic alternative (IV bisphosphonate, denosumab) when renal function is borderline

• Serum creatinine and BUN daily during the 5-day infusion — hold/stop for a rising creatinine or a value approaching ~2.5 mg/dL
• Urine output and volume status — maintain a brisk diuresis (~2 L/day) throughout
• Serum calcium (the therapeutic endpoint)
• Serum phosphate — hypophosphatemia is very common and may require repletion
• Serum magnesium and other electrolytes
• The concomitant medication list for nephrotoxins (aminoglycosides, amphotericin B, IV contrast, cisplatin)

• Warrell 1991 (J Clin Oncol) — randomized, double-blind, multicenter trial vs etidronate for cancer-related hypercalcemia: 82% vs 43% achieved normocalcemia with a longer duration of response; 97% developed asymptomatic hypophosphatemia. The registrational efficacy trial, with per-protocol creatinine monitoring.
• Crawford 1991 (Urology, SWOG) — phase II in advanced bladder carcinoma at 700 mg/m2: nephrotoxicity in 4 of the first 10 patients forced the inter-cycle interval to be lengthened; nephrotoxicity was the dose-limiting toxicity.
• Jabboury 1989 (Invest New Drugs) — phase II continuous-infusion gallium in breast cancer with oral calcium and hydration: only reversible, moderate nephrotoxicity in 2 of 15 patients, illustrating mitigation by continuous infusion plus hydration.
• Chitambar 1997 (Am J Clin Oncol) — continuous-infusion gallium plus hydroxyurea in refractory non-Hodgkin lymphoma: predominant toxicities were anemia and reversible nephrotoxicity.

• Nephrotoxicity is THE dose-limiting toxicity of gallium nitrate and the reason it is contraindicated once serum creatinine exceeds ~2.5 mg/dL.
• Volume status is everything: dehydration and concurrent nephrotoxins (aminoglycosides, amphotericin B) potentiate the injury — hydrate first and keep the patient hydrated through the full 5-day infusion.
• Give it as a slow continuous infusion, not a bolus; the continuous-infusion-plus-hydration schedules in the phase II solid-tumor trials produced only reversible, moderate azotemia.
• Expect hypophosphatemia — it occurred in ~97% of patients in the registrational hypercalcemia trial (usually asymptomatic) — and watch serum calcium fall as the therapeutic endpoint.
• The nephrotoxicity is dose-dependent: roughly 10% azotemia at the 200 mg/m2/day antihypercalcemic dose versus ~40% at the 700 mg/m2 antineoplastic dose in the SWOG bladder study.
• Largely a historical agent — IV bisphosphonates (pamidronate, zoledronate) and denosumab supplanted gallium nitrate for hypercalcemia of malignancy, in part because they are less nephrotoxic and easier to administer; Ganite was withdrawn from routine US availability.

• ADQI (2026) — The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupProvides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.Nat Rev Nephrol · PMID 41361704
• SIRM (2022) — SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.Radiol Med · PMID 35303246
• KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerIdentifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.Kidney Int · PMID 33126977
• KDIGO (2020) — KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationAddresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Kidney Int · PMID 33276867
• ADDIKD (2025) — Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceProvides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.EClinicalMedicine · PMID 40290844
• ADDIKD (2025) — Aligning kidney function assessment in patients with cancer to global practices in internal medicineThree consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.EClinicalMedicine · PMID 40290845
• ADDIKD (2025) — A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEstablishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.EClinicalMedicine · PMID 40290846
• KDIGO (2013) — Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.Crit Care · PMID 23394211
• KDIGO (2021) — Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesProvides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.Kidney Int · PMID 34556300
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisUpdates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.Kidney Int · PMID 38388147
• KDIGO (2024) — Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisUpdates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.Kidney Int · PMID 38182299
• KDIGO (2025) — Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.Kidney Int · PMID 40975525